Loading…

Serum neutralising antibody titres against a lineage 2 neuroinvasive West Nile Virus strain in response to vaccination with an inactivated lineage 1 vaccine in a European endemic area

•Inactivated vaccine is available in horses against West Nile Virus.•Inactivated lineage 1 vaccine induces antibodies against both WNV lineages.•Vaccinated animals had higher SN antibody titres against both lineages.•Protective against the clinical manifestation of WNND of the infectious strains.•Af...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary immunology and immunopathology 2020-09, Vol.227, p.110087-110087, Article 110087
Main Authors: Fehér, Orsolya, Bakonyi, Tamás, Barna, Mónika, Nagy, Anna, Takács, Mária, Szenci, Ottó, Joó, Kinga, Sárdi, Sára, Korbacska-Kutasi, Orsolya
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Inactivated vaccine is available in horses against West Nile Virus.•Inactivated lineage 1 vaccine induces antibodies against both WNV lineages.•Vaccinated animals had higher SN antibody titres against both lineages.•Protective against the clinical manifestation of WNND of the infectious strains.•After primary vaccination, yearly booster can provide proper longstanding immunity.•Vaccination protocols should be designed according to the recent epidemiologic data. In the last decade in Hungary and the neighbouring countries, West Nile Neuroinvasive Disease (WNND) has been caused in dramatically increasing numbers by lineage 2 West Nile Virus (WNV) strains both in horses and in humans. The disease in this geographical region is seasonal, so vaccination of horses should be carefully scheduled to maintain the highest antibody titres during outbreak periods. The objective of this study was to characterise the serum neutralising (SN) antibody titres against a lineage 2 WNV strain in response to vaccination with an inactivated lineage 1 vaccine (Equip® WNV). Thirty-two seronegative horses were enrolled in the study, 22 horses were allocated to the vaccinated group and 10 retained as unvaccinated controls. Horses were vaccinated according to the product’s vaccination guidelines. A primary vaccination of two doses administered 28 days apart was initiated approximately 5 months before the WNV outbreak season, followed by a booster vaccination one year later. Blood samples were collected during a 2-year period to monitor production of SN antibodies against lineage 1 and the enzootic lineage 2 WNV strain. Mean antibody titres against lineage 1 WNV were significantly higher (P ≤ 0.05) in the vaccinated group compared to the control group at all-time points after the primary dose of vaccination. Similarly, mean antibody titres against lineage 2 WNV were significantly higher (P ≤ 0.05) in the vaccinated group compared to the control group at all time-points except at 6 months after the primary vaccination. SN antibody titres were significantly higher against lineage 1 than lineage 2 at all-time points. According to the results, vaccination with an inactivated lineage 1 vaccine induces antibodies against both WNV lineages 1 and 2 strains up to 2 years after booster vaccination, but in those geographical regions where lineage 2 strains are responsible for seasonal outbreaks, a booster vaccination should be considered earlier than 12 months after primary vaccination.
ISSN:0165-2427
1873-2534
DOI:10.1016/j.vetimm.2020.110087